Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 2, 2026

China's Rare Earth Grip on the U.S. Military Is About to Break

View original at finance.yahoo.com
China's Rare Earth Grip on the U.S…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Starting from zero, it would realistically take five to seven years to build what REalloys already has

    80% confidence
  • 1% reliance on China is 100% reliance on China - if any single input comes from Beijing, entire operation is one phone call away from shutting down

    80% confidence
  • Concentrates are commodities, materials are commitments

    80% confidence
  • REalloys expects scaled production to reach 18,000 tonnes per year of heavy rare earth permanent magnets

    80% confidence
  • It isn't rare earths that are critical to national security, it's the 'rare processing' industry

    80% confidence
  • REalloys expects to be the only company with a fully operational, non-Chinese, mine-to-magnet supply chain when Pentagon deadline arrives

    80% confidence
  • REalloys expects to receive approximately 460 tonnes of defense-grade rare earth metals per year once Saskatchewan plant reaches full production

    80% confidence
  • REalloys expects to become the largest producer of refined Dysprosium and Terbium outside of China

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com